ReviewAlimentary pharmacology & therapeutics2024
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Review in Alimentary pharmacology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Systems biology framework for the rational design of operational conditions for in vitro/in vivo translation of tissue models.Science advances · 2026Article
- Article
- ATR-FTIR Assessment of the Antioxidant and Anti-Inflammatory Effects of (-)-Epicatechin in MASLD.ACS omega · 2026Article
- From bench to bedside: Molecular mechanisms, diagnostic tools, and therapeutic strategies in liver fibrosis.Liver research (Beijing, China) · 2026Review
- Radiogenomics and machine learning in hepatocellular carcinoma: from foundations to clinical translation.World journal of surgical oncology · 2026Review
- Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives.Cancers · 2026Review
- Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research Network.Hepatology communications · 2025Article
- Cadmium exposure during adolescence and young adulthood induces signatures of metabolic dysfunction-associated steatotic liver disease.Scientific reports · 2025Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances.Endocrinology, diabetes & metabolism · 2025Review
- Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes.Hepatobiliary surgery and nutrition · 2025Article
- Diagnostic Performance of Fibrosis-4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, AST-To-Platelet Ratio Index, and BARD Score Among Young and Older Adults for the Diagnosis of Advanced MASLD Fibrosis: A Retrospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Association of High-Density Lipoprotein Cholesterol-Based Inflammatory Markers With MASLD and Significant Liver Fibrosis in US Adults: Insights From NHANES 2017-2020.Clinical and translational gastroenterology · 2025Article
- Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction-Associated Steatotic Liver Disease.Alimentary pharmacology & therapeutics · 2025Article
- Relative fat mass and risk of metabolic dysfunction associated steatotic liver disease and severe hepatic steatosis in U.S. adults: analysis of NHANES 2017-2020 data.BMC gastroenterology · 2025Article
- Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases.Journal of clinical medicine · 2025Article
- Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.Journal of clinical medicine · 2025Review
- Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis.Frontiers in pharmacology · 2025Review
- From Mind to Liver: Exploring the Causal Relationship Between Anxiety Disorders and Non-Alcoholic Fatty Liver Disease Through Mendelian Randomization and UK Biobank Validation.Journal of multidisciplinary healthcare · 2025Article
- Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Assessing Quality of Ultrasound Attenuation Coefficient Results for Liver Fat Quantification.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Its prevalence is increasing with the epidemic of obesity and metabolic syndrome. MASLD progression into metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis may lead to decompensated cirrhosis and development of liver-related events, hepatocellular carcinoma and death. Monitoring disease progression is critical in decreasing morbidity, mortality, need for transplant and economic burden. Assessing for treatment response once FDA-approved medications are available is still an unmet clinical need.
aimsTo explore the most up-to-date literature on testing used for monitoring disease progression and treatment response
methodsWe searched PubMed from inception to 15 August 2023, using the following MeSH terms: 'MASLD', 'Metabolic dysfunction-associated steatotic liver disease', 'MASH', 'metabolic dysfunction-associated steatohepatitis', 'Non-Alcoholic Fatty Liver Disease', 'NAFLD', 'non-alcoholic steatohepatitis', 'NASH', 'Biomarkers', 'clinical trial'. Articles were also identified through searches of the authors' files. The final reference list was generated based on originality and relevance to this review's broad scope, considering only papers published in English.
resultsWe have cited 101 references in this review detailing methods to monitor MASLD disease progression and treatment response.
conclusionVarious biomarkers can be used in different care settings to monitor disease progression. Further research is needed to validate noninvasive tests more effectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.